Glucose Viaflo Baxter Médico Farmacêutica

Glucose Viaflo Baxter Médico Farmacêutica is an intravenous solution for injection containing glucose monohydrate as the sole active ingredient. It is supplied as a sterile aqueous solution intended for parenteral administration. The product is manufactured in the European Union and is classified as a excipient/solvent used in parenteral nutrition and fluid replacement. It provides a carbohydrate source for correction of low blood glucose or as part of total nutrient admixtures.

Glucose Viaflo is indicated for several clinical situations where intravenous carbohydrate delivery is required in acute care.

- Treatment of acute hypoglycemia in patients unable to take oral glucose. - Component of standard parenteral nutrition regimens to meet daily caloric needs. - Fluid and electrolyte replacement when combined with appropriate electrolyte solutions. - Dilution medium for intravenous drug admixtures that require a carbohydrate base for stability. - Support during peri‑operative fasting to maintain stable plasma glucose levels. - Emergency management of insulin‑induced hypoglycemia during cardiac arrest resuscitation protocols.

Adverse reactions to intravenous glucose solutions are generally related to the osmotic load and the carbohydrate content.

Common: - Transient hyperglycemia when administered to patients with normal glucose regulation. - Local irritation or pain at the infusion site. - Mild electrolyte shifts, particularly sodium and potassium, due to dilution. - Mild nausea or vomiting when infused rapidly. - Headache related to rapid changes in plasma osmolality. - Transient increase in serum lactate levels.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload in patients with compromised cardiac or renal function. - Allergic or anaphylactoid reactions, although rare. - Development of hyperosmolar hyperglycemic state in susceptible individuals. - Severe electrolyte imbalance such as hypernatremia or hypokalemia. - Severe hyperglycemia leading to osmotic diuresis.

When prescribing Glucose Viaflo, clinicians should evaluate patient-specific factors to minimize risks associated with intravenous carbohydrate administration.

- Assess baseline blood glucose and adjust infusion rate in diabetic or hypoglycemic patients. - Monitor fluid balance and avoid excessive volumes in patients with heart failure or renal impairment. - Use compatible IV sets and avoid mixing with calcium‑containing solutions that may precipitate. - Check serum electrolytes before and during therapy, especially sodium, potassium, and magnesium. - Consider the osmolarity of the solution; dilute appropriately for peripheral administration. - Evaluate for a history of hypersensitivity to glucose preparations. - Avoid rapid bolus administration unless clinically indicated.

Glucose Viaflo may interact with other intravenous agents or affect the pharmacodynamics of certain medications.

Avoid: - Co‑administration with high‑dose insulin infusions without glucose monitoring. - Mixing with calcium or phosphate solutions that can cause precipitation. - Simultaneous infusion of hypertonic dextrose solutions exceeding recommended osmolarity. - Concurrent infusion with potassium chloride solutions may increase risk of hyperkalemia.

Use with caution: - Concurrent use of diuretics that may exacerbate electrolyte shifts. - Administration in patients receiving beta‑blockers, as hypoglycemia signs may be masked. - Overlap with total parenteral nutrition formulations; adjust carbohydrate content to avoid excess calories. - Patients on corticosteroid therapy may experience altered glucose metabolism; monitor levels closely.